One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment
Obesity · 2026
DOI: 10.1002/oby.70043 ↗At a glance
Klinische Studie (Phase IV) in Obesity, 2026. Written by Joachim Holt and 11 co-authors. Institution: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Major MEDLINE topics: Exercise, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Liraglutide. Cited 1 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Novo Nordisk, Cambridge Weight Plan, Helsefonden.
Abstract (original language)
Objective
Incretin‐based obesity medication maintains weight loss by mimicking the appetite‐inhibiting hormone GLP‐1. Interestingly, chronic exercise may improve postprandial appetite control by increasing late postprandial secretion of endogenous GLP‐1. Therefore, we investigated whether an exercise program after weight loss could increase late‐phase postprandial GLP‐1 secretion.
Methods
This study is an exploratory analysis of adults with obesity ( n = 195) who lost 13.1 kg on a low‐calorie diet and were randomized to 52 weeks of either usual activity, moderate‐to‐vigorous intensity exercise, the GLP‐1 receptor agonist liraglutide (3.0 mg/day), or the combination. The primary endpoint was change in late‐phase GLP‐1 response to a 3‐h liquid mixed meal test before and after diet‐induced weight loss and after 1 year of intervention.
Results
Diet‐induced weight loss did not change late‐phase GLP‐1 response (3%; 95% CI, −4%–10%). One year of exercise increased late‐phase postprandial GLP‐1 response within the group by 37% (95% CI, 20%–57%), and this increase was 25% greater (95% CI, 3%–51%, p = 0.02) compared to the usual activity group. Late‐phase postprandial GLP‐1 response was unchanged in both groups treated with GLP‐1 receptor agonist compared to placebo.
Conclusions
One year of exercise increased late‐phase postprandial GLP‐1 response, which may prevent increased appetite after weight loss and thereby weight regain. Trial Registration EudraCT number: 2015–005585‐32; ClinicalTrials.gov identifier: NCT04122716
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- NNF Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Endocrinology, Hvidovre University Hospital, Copenhagen, Denmark.
ORCID profiles: Joachim Holt, Sten Madsbad, Signe Sørensen Torekov
Funding
- Novo Nordisk
- Cambridge Weight Plan
- Helsefonden
- Danish Cardiovascular Academy
- Novo Nordisk Fonden
Cite
APA
Holt, J., Sandsdal, R. M., Byberg, S., Janus, C., Juhl, C. R., Jørgensen, J. R., Hartmann, B., Stallknecht, B., Holst, J. J., Madsbad, S., Jensen, S. B. K., & Torekov, S. S. (2026). One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment. Obesity. https://doi.org/10.1002/oby.70043
Vancouver
Holt J, Sandsdal RM, Byberg S, Janus C, Juhl CR, Jørgensen JR, et al. One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment. Obesity. 2026. doi:10.1002/oby.70043
BibTeX
@article{Holt2026,
author = {Holt, Joachim and Sandsdal, Rasmus Michael and Byberg, Sarah and Janus, Charlotte and Juhl, Christian Rimer and Jørgensen, Julie Rehné and Hartmann, Bolette and Stallknecht, Bente and Holst, Jens Juul and Madsbad, Sten and Jensen, Simon Birk Kjær and Torekov, Signe Sørensen},
title = {One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70043}
}
EUVIMED